---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-21-001785"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2021-12-02T23:59:59+00:00"
generated_at: "2026-06-28T04:05:26.215950+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# IGC Phase 1 trial for THC-based Alzheimer's drug IGC-AD1 shows statistically significant NPI reductions; no SAEs

## Summary
- Mean NPI decreased from baseline 31.5 to 16.7 on day 10 (p=0.0044) in Cohort 1; improvements in agitation, anxiety, appetite disorders.
- No serious adverse events or deaths across all cohorts; only one related AE (mild dizziness) reported.
- IGC plans to design a larger multi-site Phase 2/3 trial pending FDA approval for IGC-AD1.
- Sixty-two percent of participants had CYP2C9 intermediate metabolizer phenotype, affecting THC half-life (5.09 h vs 1.73 h for normal).

## SEC filing metadata
- accession: 0001185185-21-001785
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2021-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518521001785/0001185185-21-001785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518521001785/indiaglob20211130_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-21-001785
- JSON: https://secwatch.observer/filing/0001185185-21-001785.json
- Plain text: https://secwatch.observer/filing/0001185185-21-001785.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.